Back
Open Access

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.

Session: Interventions to improve outcomes in cardio-oncology
Topic: Cardio-Oncology
Speaker: Doctor S. Maragkoudakis (Chania, GR)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)
0 follower

4 more presentations in this session

Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study

Speaker: Doctor I. Martins Moreira (Vila Real, PT)

Access
Abstract
Like
Thumbnail

Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors

Speaker: Doctor M. Slieman (Tel Aviv, IL)

Access
Abstract
Like
Thumbnail

Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort

Speaker: Doctor I. Araujo (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Cardiotoxicity and immune checkpoint inhibitors: a heartfelt myth or the real deal?

Speaker: Doctor S. Esteves (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Access the full session

Interventions to improve outcomes in cardio-oncology

Speakers: Doctor S. Maragkoudakis, Doctor I. Martins Moreira, Doctor M. Slieman, Doctor I. Araujo, Doctor S. Esteves
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources